Literature DB >> 24214089

Reassessment of the role of the central cholinergic system.

Anna Hrabovska1, Eric Krejci.   

Abstract

The central cholinergic system is believed to be involved in the control of many physiological functions and is an important pharmacological target for numerous neurological pathologies. Here, we summarize our recent observations regarding this topic that we obtained by studying genetically modified mice devoid of particular cholinesterase molecular forms. Our results, collected from mice with deficits of functional cholinesterases in the brain, suggest that the increase in the level of acetylcholine (ACh) has an impact on cognition only in the situation when extracellular ACh is low. Furthermore, we confirmed the central control of movement coordination, which could be of importance for the management of motor problems in patients with Parkinson's disease. At last, we provide clear evidence that while the hypothermic effect of the muscarinic agonist oxotremorine is based on a central mechanism, in contrast, the acetylcholinesterase inhibitor donepezil decreases body temperature by its action in the periphery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24214089     DOI: 10.1007/s12031-013-0164-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  60 in total

Review 1.  Intraneuronal trafficking of G-protein-coupled receptors in vivo.

Authors:  Véronique Bernard; Marion Décossas; Isabel Liste; Bertrand Bloch
Journal:  Trends Neurosci       Date:  2006-01-27       Impact factor: 13.837

Review 2.  The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states.

Authors:  Yoland Smith; Dinesh Raju; Bijli Nanda; Jean-Francois Pare; Adriana Galvan; Thomas Wichmann
Journal:  Brain Res Bull       Date:  2008-09-19       Impact factor: 4.077

Review 3.  Integration and central processing in temperature regulation.

Authors:  C J Gordon; J E Heath
Journal:  Annu Rev Physiol       Date:  1986       Impact factor: 19.318

4.  Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain.

Authors:  M Abitbol; C Menini; A L Delezoide; T Rhyner; M Vekemans; J Mallet
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

Review 5.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

6.  Comparisons of the acute effects of cholinesterase inhibitors using a neurobehavioral screening battery in rats.

Authors:  V C Moser
Journal:  Neurotoxicol Teratol       Date:  1995 Nov-Dec       Impact factor: 3.763

7.  Knockout of one acetylcholinesterase allele in the mouse.

Authors:  W Xie; P J Wilder; J Stribley; A Chatonnet; A Rizzino; P Taylor; S H Hinrichs; O Lockridge
Journal:  Chem Biol Interact       Date:  1999-05-14       Impact factor: 5.192

8.  Delivery of human acetylcholinesterase by adeno-associated virus to the acetylcholinesterase knockout mouse.

Authors:  Anna Hrabovska; Ellen G Duysen; Jeffrey D Sanders; L Charles Murrin; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2005-10-21       Impact factor: 5.192

9.  Distinct localization of collagen Q and PRiMA forms of acetylcholinesterase at the neuromuscular junction.

Authors:  Véronique Bernard; Emmanuelle Girard; Anna Hrabovska; Shelley Camp; Palmer Taylor; Benoit Plaud; Eric Krejci
Journal:  Mol Cell Neurosci       Date:  2010-09-29       Impact factor: 4.314

10.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy.

Authors:  E C Hirsch; A M Graybiel; C Duyckaerts; F Javoy-Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

View more
  1 in total

1.  Dysfunctional Presynaptic M2 Receptors in the Presence of Chronically High Acetylcholine Levels: Data from the PRiMA Knockout Mouse.

Authors:  Franziska Mohr; Eric Krejci; Martina Zimmermann; Jochen Klein
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.